NCT02069730 2026-01-08
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
University Health Network, Toronto
Phase NA Completed
Clinical Trials
8 trialsNCT03110562 2024-08-21
BOSTON
Karyopharm Therapeutics Inc
Phase 3 Completed
NCT06212596 2024-01-19
MUKtwelve
University of Leeds
Phase 2 Completed
NCT03944057 2023-06-15
MARCH
Antengene Corporation
Phase 2 Completed
NCT02186834 2023-01-04
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT02249091 2021-08-25
A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
GSO Global Clinical Research BV
Phase 2 Completed
NCT03661515 2020-05-20
FLAGINEXOR
PETHEMA Foundation
Phase 1 Completed
NCT02530476 2020-03-31
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed